Life Technologies made yet another acquisition and announced that it will be acquiring Compendia Bioscience, a cancer bioinformatics company based at Ann Arbor, MI. Compendia Bioscience was founded in 2006 by Arul Chinnaiyan, a Univ. Michigan professor and Dan Rhodes a researcher at U. Michigan.
Compendia Bioscience was started with the mission of using genomic data to cure cancer, especially using gene expression data to diagnose and understand the cancer type. Compendia already has gathered rich source data from over 62,000 cancer patients. Compendia’s cloud based bioinformatics tools, “Oncomine” technology offers solution for complex data mining and visualization to facilitate target discovery and validation.
This is the third acquisition in personal genetics/genomics space by Life technologies in the last few months, Earlier, Life Technologies acquired Navigenics and Pinpoint Genomics. In the press release announcing the acquisition of Compendia Bioscience, Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies, said that
We have created the optimal foundation to drive progress in personalized medicine. By combining the acquisitions of Pinpoint Genomics, Navigenics and Compendia, we now possess the full spectrum capability to develop and commercialize high-value cancer diagnostics where there is currently great unmet need.
Daniel R. Rhodes, Compendia’s CEO and co-founder, said
Compendia has become an integral part of the pharmaceutical industry’s cancer drug discovery programs, and in joining Life Technologies, we’ll gain the opportunity to expand the utility of Compendia even further.
With the acquisition, the co-founder Daniel R. Rhodes will join Life Technologies to work expanding the scope in personalized medicine. While the other co-founder Arul Chinnaiyan, M.D., Ph.D. will serve as strategic advisor to Life Technologies.